BMY vs PFE
Bristol-Myers Squibb Company and Pfizer Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | BMY | PFE |
|---|---|---|
| Revenue | $48.2B | $62.6B |
| Net income | $7.1B | $7.8B |
| Gross margin | 71.1% | 74.3% |
| Net margin | 14.6% | 12.4% |
| Return on equity | 40.5% | 8.9% |
| Diluted EPS | $3.46 | $1.36 |
| Dividend / share | $2.49 | $1.72 |
| Payout ratio | 71.5% | — |
| Free cash flow | $12.8B | $9.1B |
| Equity | $18.5B | $86.5B |
| Net debt / equity | 1.87× | 0.73× |
| Current ratio | 1.26× | 1.16× |
| Revenue CAGR 5y | 2.5% | 8.5% |
| Profit CAGR 5y | — | −3.2% |
PFE bills 1.3× the revenue of BMY, and BMY keeps more of each dollar of revenue as profit (14.6% against 12.4%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | BMY | PFE |
|---|---|---|
| FY2025 | $48.2B | $62.6B |
| FY2024 | $48.3B | $63.6B |
| FY2023 | $45.0B | $59.6B |
| FY2022 | $46.2B | $101.2B |
| FY2021 | $46.4B | $73.6B |
| FY2020 | $42.5B | $41.7B |
| FY2019 | $26.1B | $40.9B |
| FY2018 | $22.6B | $40.8B |
| FY2017 | $20.8B | $52.5B |
| FY2016 | $19.4B | $52.8B |
Net income by year
Bottom line
| Fiscal year | BMY | PFE |
|---|---|---|
| FY2025 | $7.1B | $7.8B |
| FY2024 | $-8.9B | $8.0B |
| FY2023 | $8.0B | $2.1B |
| FY2022 | $6.3B | $31.4B |
| FY2021 | $7.0B | $22.0B |
| FY2020 | $-9.0B | $9.2B |
| FY2019 | $3.4B | $16.0B |
| FY2018 | $4.9B | $11.2B |
| FY2017 | $1.0B | $21.3B |
| FY2016 | $4.5B | $7.2B |
Advertisement
AdSense · Rectangle 336×280